EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids

Emily Nghiem iD, Ariel Tzamarot iD, Terence Li iD, Zimo Huang iD, Mahshid Mohammadi, Dior Dedushi iD, Yvonne Saenger, Fernand Bteich iD, Chaoyuan Kuang iD

Pharmaceutics · 30.05.2026 · 18 (6) · 683

DOI: 10.3390/pharmaceutics18060683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.05.2026. Verfasst von Emily Nghiem und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, NY 10467, USA. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: PI3K/AKT/mTOR is a key pathway in cell proliferation, metabolism, and survival. Activating PIK3CA mutations are seen in up to 20% of colorectal cancers and are associated with increased cyclo-oxygenase-2 (COX-2) expression. Recent studies demonstrated a significant survival benefit from taking low-dose aspirin, a nonselective COX inhibitor, supporting further exploration of the synergistic effects of combined PI3Kα inhibitor (inavolisib) and COX-2 inhibitor (celecoxib) therapy.

Methods

The effects of celecoxib–inavolisib combination treatment were tested on human colorectal cancer cell lines and patient-derived organoid models. Experiments included cell viability and colony formation assays, immunoblotting, and immunofluorescence.

Results

We found that celecoxib and inavolisib demonstrated synergy in suppressing the growth of colorectal cancer cell lines, grown in both 2D and 3D cell culture, regardless of PIK3CA mutation status. In patient-derived organoid models, while synergy was seen in both organoids, growth of the PIK3CA mutated organoid was more potently suppressed. Immunoblotting of cells after combination treatment showed decreased expression of mitogenic signaling marker p-AKT across all 2D cell lines and in both cell lines grown as 3D spheroids, as well as increased expression of apoptotic marker cPARP in four out of five 2D cell lines and in both cell lines grown as 3D spheroids. Immunofluorescence staining of organoids after combination treatment, however, showed no significant increase in expression of apoptotic marker Cas-3 nor in mitogenic marker Ki-67 in either organoid. Furthermore, an apoptosis assay performed on two cell lines showed no significant increase in Annexin V or phosphatidylserine staining.

Conclusions

Celecoxib and inavolisib demonstrated synergy in suppressing the growth of both colorectal cancer cell lines and patient-derived organoids, though PIK3CA mutation status did not appear to affect drug efficacy in cell lines as it did in patient-derived organoids. Potential compensatory or resistance mechanisms might include oncogene drivers in the MAPK/ERK pathway. When compared to monotherapy, combination therapy was the only drug condition to significantly increase the percentage of apoptotic cells based on Annexin V and phosphatidylserine staining, and this effect was only seen in the PIK3CA mutated cell line. Ultimately, our findings provide preliminary support for celecoxib–inavolisib combination treatment as a rational therapeutic avenue warranting further preclinical investigation.

Schlagwörter

Stichwörter der Autor:innen

COX-2PI3KαPIK3CAcelecoxibcolorectal cancerinavolisiborganoidspreclinical study

Autor:innen und Institutionen

  • Department of Surgery, Albert Einstein College of Medicine, and Montefiore Medical Center, Bronx, NY 10467, USA.
  • Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • Department of Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

ORCID-Profile: Emily Nghiem, Ariel Tzamarot, Terence Li, Zimo Huang, Dior Dedushi, Fernand Bteich, Chaoyuan Kuang

Förderung

  • NIH HHS
  • NIH

Zitieren

APA

Nghiem, E., Tzamarot, A., Li, T., Huang, Z., Mohammadi, M., Dedushi, D., Saenger, Y., Bteich, F., & Kuang, C. (2026). Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids. Pharmaceutics, 18(6), 683. https://doi.org/10.3390/pharmaceutics18060683

Vancouver

Nghiem E, Tzamarot A, Li T, Huang Z, Mohammadi M, Dedushi D, et al. Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids. Pharmaceutics. 2026;18(6):683. doi:10.3390/pharmaceutics18060683

BibTeX
@article{Nghiem2026,
  author = {Nghiem, Emily and Tzamarot, Ariel and Li, Terence and Huang, Zimo and Mohammadi, Mahshid and Dedushi, Dior and Saenger, Yvonne and Bteich, Fernand and Kuang, Chaoyuan},
  title = {Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {683},
  doi = {10.3390/pharmaceutics18060683}
}
Kostenlos starten →